Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	71.43	648.61	71.79	66.42	63.84
Short-Term Investments	114.82	0	0	0	0
Cash & Cash Equivalents	186.24	648.61	71.79	66.42	63.84
Cash Growth	-71.29%	803.47%	8.09%	4.03%	90.16%
Receivables	0	0.35	1.46	0.33	0.54
Other Current Assets	3.47	7.76	24.06	20.93	15.25
Total Current Assets	189.71	656.71	97.31	87.67	79.63
Property, Plant & Equipment	6.06	5.08	3.48	1.28	1.54
Goodwill and Intangibles	1.89	1.8	12.41	13.55	15.08
Other Long-Term Assets	5.28	0.58	0.17	0	0
Total Long-Term Assets	13.24	7.46	16.06	14.82	16.62
Total Assets	202.95	664.17	113.37	102.5	96.25
Accounts Payable	2.67	0.36	4.37	6.14	4.47
Deferred Revenue	0	0	7.94	8.94	3.11
Current Debt	2.81	21.46	1.09	0.39	0.47
Other Current Liabilities	14.93	16.97	12.22	4.42	5.72
Total Current Liabilities	20.41	38.78	25.62	19.89	13.77
Long-Term Debt	103.29	497.3	1.69	0.08	0.42
Other Long-Term Liabilities	1.56	1.43	2.78	3.08	3.2
Total Long-Term Liabilities	104.85	498.73	4.47	3.16	3.62
Total Liabilities	125.26	537.51	30.09	23.05	17.39
Total Debt	106.1	518.76	2.78	0.47	0.89
Debt Growth	-79.55%	18547.12%	498.28%	-47.93%	-28.92%
Retained Earnings	-993.26	-378.33	-299.55	-210.95	-158.25
Comprehensive Income	-2.45	-1.89	-2.2	-3.79	-4.76
Shareholders' Equity	77.69	126.65	83.28	79.45	78.86
Net Cash / Debt	80.14	129.84	69.01	65.95	62.95
Net Cash / Debt Growth	-38.28%	88.16%	4.64%	4.77%	94.79%
Net Cash Per Share	0.13	0.67	0.52	0.95	-
Working Capital	169.31	617.93	71.69	67.78	65.86
Book Value Per Share	0.13	0.66	0.63	1.14	2.46

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).